{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:29:42Z","timestamp":1789882182004,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100014517","name":"Louisiana Biomedical Research Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014517","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00011-022-01572-4","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T18:04:57Z","timestamp":1652724297000},"page":"711-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague\u2013Dawley rats fed a high-cholesterol diet"],"prefix":"10.1007","volume":"71","author":[{"given":"Rashmi","family":"Pathak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry A.","family":"Palfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten P.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan R.","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Gettys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4338-2542","authenticated-orcid":false,"given":"Subramanyam N.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"issue":"1","key":"1572_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"3","key":"1572_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi Z. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274\u201385.","journal-title":"Aliment Pharmacol Ther"},{"key":"1572_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/liv.13299","volume":"37","author":"S Bellentani","year":"2017","unstructured":"Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37:81\u20134.","journal-title":"Liver Int"},{"issue":"1","key":"1572_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-05040-6","volume":"7","author":"LN Tu","year":"2017","unstructured":"Tu LN, Showalter MR, Cajka T, Fan S, Pillai VV, Fiehn O, et al. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice. Sci Rep. 2017;7(1):1\u201314.","journal-title":"Sci Rep"},{"issue":"5","key":"1572_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/hep.26088","volume":"56","author":"TA Kerr","year":"2012","unstructured":"Kerr TA, Davidson NO. Cholesterol and NAFLD: renewed focus on an old villain. Hepatol (Baltimore, MD). 2012;56(5):1995.","journal-title":"Hepatol (Baltimore, MD)"},{"issue":"9","key":"1572_CR6","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.bbadis.2015.05.015","volume":"1852","author":"G Arguello","year":"2015","unstructured":"Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim et Biophys Acta BBA Mol Basis Dis. 2015;1852(9):1765\u201378.","journal-title":"Biochim et Biophys Acta BBA Mol Basis Dis"},{"key":"1572_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DMSO.S146339","volume":"11","author":"R Sarwar","year":"2018","unstructured":"Sarwar R, Pierce N, Koppe S. Obesity and nonalcoholic fatty liver disease: current perspectives. Diabetes Metab Syndrome Obes Targets Ther. 2018;11:533.","journal-title":"Diabetes Metab Syndrome Obes Targets Ther"},{"issue":"2","key":"1572_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.23280","volume":"51","author":"E Fabbrini","year":"2010","unstructured":"Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679\u201389.","journal-title":"Hepatology"},{"key":"1572_CR9","first-page":"1","volume":"8","author":"G Targher","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus\u2014mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;8:1\u201314.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1572_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/HMER.S158053","volume":"10","author":"S Alam","year":"2018","unstructured":"Alam S, Ghosh J, Mustafa G, Kamal M, Ahmad N. Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial. Hepatic Med Evid Res. 2018;10:23.","journal-title":"Hepatic Med Evid Res"},{"issue":"3","key":"1572_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00535-013-0783-4","volume":"49","author":"K Kaji","year":"2014","unstructured":"Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Douhara A, et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol. 2014;49(3):481\u201391.","journal-title":"J Gastroenterol"},{"issue":"2","key":"1572_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1042\/CS20100372","volume":"120","author":"B Maiztegui","year":"2011","unstructured":"Maiztegui B, Borelli MI, Madrid VG, Del Zotto H, Raschia MA, Francini F, et al. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased \u03b2-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci. 2011;120(2):73\u201380.","journal-title":"Clin Sci"},{"issue":"4","key":"1572_CR13","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db10-1338","volume":"60","author":"J Shirakawa","year":"2011","unstructured":"Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011;60(4):1246\u201357.","journal-title":"Diabetes"},{"issue":"4","key":"1572_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/met.2012.0128","volume":"11","author":"SB Akaslan","year":"2013","unstructured":"Akaslan SB, Degertekin CK, Yilmaz G, Cakir N, Arslan M, Toruner FB. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats. Metab Syndr Relat Disord. 2013;11(4):243\u201350.","journal-title":"Metab Syndr Relat Disord"},{"issue":"6","key":"1572_CR15","doi-asserted-by":"publisher","first-page":"38744","DOI":"10.1371\/journal.pone.0038744","volume":"7","author":"M Kern","year":"2012","unstructured":"Kern M, Kl\u00f6ting N, Niessen HG, Thomas L, Stiller D, Mark M, et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS ONE. 2012;7(6):38744.","journal-title":"PLoS ONE"},{"issue":"3","key":"1572_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00795-013-0053-9","volume":"47","author":"T Klein","year":"2014","unstructured":"Klein T, Fujii M, Sandel J, Shibazaki Y, Wakamatsu K, Mark M, et al. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Med Mol Morphol. 2014;47(3):137\u201349.","journal-title":"Med Mol Morphol"},{"issue":"6","key":"1572_CR17","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.2337\/db14-0804","volume":"64","author":"AR Aroor","year":"2015","unstructured":"Aroor AR, Habibi J, Ford DA, Nistala R, Lastra G, Manrique C, et al. Dipeptidyl peptidase-4 inhibition ameliorates Western diet\u2013induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function. Diabetes. 2015;64(6):1988\u20132001.","journal-title":"Diabetes"},{"issue":"43","key":"1572_CR18","doi-asserted-by":"publisher","first-page":"16227","DOI":"10.3748\/wjg.v20.i43.16227","volume":"20","author":"T Ohyama","year":"2014","unstructured":"Ohyama T, Sato K, Yamazaki Y, Hashizume H, Horiguchi N, Kakizaki S, et al. MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob\/ob mice. World J Gastroenterol: WJG. 2014;20(43):16227.","journal-title":"World J Gastroenterol: WJG"},{"issue":"2","key":"1572_CR19","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1159\/000341510","volume":"6","author":"M Itou","year":"2012","unstructured":"Itou M, Kawaguchi T, Taniguchi E, Oriishi T, Sata M. Dipeptidyl peptidase IV inhibitor improves insulin resistance and steatosis in a refractory nonalcoholic fatty liver disease patient: a case report. Case Rep Gastroenterol. 2012;6(2):538\u201344.","journal-title":"Case Rep Gastroenterol"},{"issue":"112","key":"1572_CR20","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.5754\/hge11263","volume":"58","author":"T Iwasaki","year":"2011","unstructured":"Iwasaki T, Yoneda M, Inamori M, Shirakawa J, Higurashi T, Maeda S, et al. Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology. 2011;58(112):2103\u20135.","journal-title":"Hepatogastroenterology"},{"issue":"2","key":"1572_CR21","first-page":"240","volume":"75","author":"Y Yilmaz","year":"2012","unstructured":"Yilmaz Y, Yonal O, Deyneli O, Celikel CA, Kalayci C, Duman DG. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastro-Enterol Belg. 2012;75(2):240\u20134.","journal-title":"Acta Gastro-Enterol Belg"},{"key":"1572_CR22","first-page":"1662","volume":"20","author":"I Kanazawa","year":"2014","unstructured":"Kanazawa I, Tanaka K-I, Sugimoto T. DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus. Med Sci Monit Int Med J Exp Clin Res. 2014;20:1662.","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"issue":"5","key":"1572_CR23","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1253\/circj.CJ-12-1168","volume":"77","author":"J Matsubara","year":"2013","unstructured":"Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77(5):1337\u201344.","journal-title":"Circ J"},{"issue":"11","key":"1572_CR24","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3346\/jkms.2012.27.11.1364","volume":"27","author":"Y Kubota","year":"2012","unstructured":"Kubota Y, Miyamoto M, Takagi G, Ikeda T, Kirinoki-Ichikawa S, Tanaka K, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci. 2012;27(11):1364\u201370.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"1572_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/eurjhf\/hfr146","volume":"14","author":"N Gomez","year":"2012","unstructured":"Gomez N, Touihri K, Matheeussen V, Da Costa AM, Mahmoudabady M, Mathieu M, et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012;14(1):14\u201321.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1572_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-12-35","volume":"12","author":"Y Sakamoto","year":"2013","unstructured":"Sakamoto Y, Oyama JI, Ikeda H, Kuroki S, Gondo S, Iwamoto T, et al. Effects of sitagliptin beyond glycemic control: focus on quality of life. Cardiovasc Diabetol. 2013;12(1):1\u20139.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1572_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.taap.2014.01.021","volume":"276","author":"R Rouse","year":"2014","unstructured":"Rouse R, Xu L, Stewart S, Zhang J. High fat diet and GLP-1 drugs induce pancreatic injury in mice. Toxicol Appl Pharmacol. 2014;276(2):104\u201314.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1572_CR28","doi-asserted-by":"crossref","unstructured":"Shahbaz A, Aziz K, Umair M, Sharifzadeh M, Sachmechi I. Acute liver injury induced by sitagliptin: report of two cases and review of literature. Cureus. 2018;10(6).","DOI":"10.7759\/cureus.2776"},{"issue":"9","key":"1572_CR29","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2169\/internalmedicine.50.5057","volume":"50","author":"M Toyoda-Akui","year":"2011","unstructured":"Toyoda-Akui M, Yokomori H, Kaneko F, Shimizu Y, Takeuchi H, Tahara K, et al. A case of drug-induced hepatic injury associated with sitagliptin. Intern Med. 2011;50(9):1015\u201320.","journal-title":"Intern Med"},{"issue":"6","key":"1572_CR30","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jchf.2017.12.016","volume":"6","author":"M Packer","year":"2018","unstructured":"Packer M. Worsening heart failure during the use of DPP-4 inhibitors: pathophysiological mechanisms, clinical risks, and potential influence of concomitant antidiabetic medications. JACC Heart Fail. 2018;6(6):445\u201351.","journal-title":"JACC Heart Fail"},{"issue":"7","key":"1572_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00011-019-01243-x","volume":"68","author":"R Pathak","year":"2019","unstructured":"Pathak R, Kumar A, Palfrey HA, Forney LA, Stone KP, Raju NR, et al. The incretin enhancer, sitagliptin, exacerbates expression of hepatic inflammatory markers in rats fed a high-cholesterol diet. Inflamm Res. 2019;68(7):581\u201395.","journal-title":"Inflamm Res"},{"issue":"1","key":"1572_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12986-019-0422-z","volume":"17","author":"A Kumar","year":"2020","unstructured":"Kumar A, Pathak R, Palfrey HA, Stone KP, Gettys TW, Murthy SN. High levels of dietary methionine improves sitagliptin-induced hepatotoxicity by attenuating oxidative stress in hypercholesterolemic rats. Nutr Metab. 2020;17(1):1\u201314.","journal-title":"Nutr Metab"},{"issue":"1","key":"1572_CR33","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/j.pbj.0000000000000012","volume":"3","author":"GP P\u00fcschel","year":"2018","unstructured":"P\u00fcschel GP, Henkel J. Dietary cholesterol does not break your heart but kills your liver. Porto Biomed J. 2018;3(1):e12.","journal-title":"Porto Biomed J"},{"key":"1572_CR34","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3389\/fmed.2020.00467","volume":"7","author":"P Malhotra","year":"2020","unstructured":"Malhotra P, Gill RK, Saksena S, Alrefai WA. Disturbances in cholesterol homeostasis and non-alcoholic fatty liver diseases. Front Med. 2020;7:467.","journal-title":"Front Med"},{"issue":"44","key":"1572_CR35","doi-asserted-by":"publisher","first-page":"42774","DOI":"10.1074\/jbc.M306022200","volume":"278","author":"L Vergnes","year":"2003","unstructured":"Vergnes L, Phan J, Tafuri S, Reue K, Strauss M. Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J Biol Chem. 2003;278(44):42774\u201384.","journal-title":"J Biol Chem"},{"issue":"3","key":"1572_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jnutbio.2014.11.002","volume":"26","author":"JE Mells","year":"2015","unstructured":"Mells JE, Fu PP, Kumar P, Smith T, Karpen SJ, Anania FA. Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. J Nutr Biochem. 2015;26(3):285\u201392.","journal-title":"J Nutr Biochem"},{"key":"1572_CR37","doi-asserted-by":"crossref","unstructured":"Angelico F, Ferro D, Baratta F. Is the mediterranean diet the best approach to NAFLD treatment today? Multidisciplinary Digital Publishing Institute; 2021.","DOI":"10.3390\/nu13030739"},{"issue":"2","key":"1572_CR38","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1017\/S095442241600007X","volume":"29","author":"Z Hosseini","year":"2016","unstructured":"Hosseini Z, Whiting SJ, Vatanparast H. Current evidence on the association of the metabolic syndrome and dietary patterns in a global perspective. Nutr Res Rev. 2016;29(2):152\u201362.","journal-title":"Nutr Res Rev"},{"issue":"4","key":"1572_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/liv.12990","volume":"36","author":"M Razavi Zade","year":"2016","unstructured":"Razavi Zade M, Telkabadi MH, Bahmani F, Salehi B, Farshbaf S, Asemi Z. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial. Liver Int. 2016;36(4):563\u201371.","journal-title":"Liver Int"},{"issue":"130","key":"1572_CR40","first-page":"323","volume":"61","author":"T Fukuhara","year":"2014","unstructured":"Fukuhara T, Hyogo H, Ochi H, Fujino H, Kan H, Naeshiro N, et al. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology. 2014;61(130):323\u20138.","journal-title":"Hepatogastroenterology"},{"issue":"11","key":"1572_CR41","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/hepr.12077","volume":"43","author":"Y Arase","year":"2013","unstructured":"Arase Y, Kawamura Y, Seko Y, Kobayashi M, Suzuki F, Suzuki Y, et al. Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease. Hepatol Res. 2013;43(11):1163\u20138.","journal-title":"Hepatol Res"},{"issue":"2","key":"1572_CR42","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","volume":"65","author":"J Cui","year":"2016","unstructured":"Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, et al. Sitagliptin vs placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2016;65(2):369\u201376.","journal-title":"J Hepatol"},{"issue":"1","key":"1572_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","volume":"23","author":"TR Joy","year":"2017","unstructured":"Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, et al. Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial. World J Gastroenterol. 2017;23(1):141.","journal-title":"World J Gastroenterol"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-022-01572-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-022-01572-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-022-01572-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T15:05:37Z","timestamp":1668351937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-022-01572-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":43,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1572"],"URL":"https:\/\/doi.org\/10.1007\/s00011-022-01572-4","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"4 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experimental procedures and protocols involved in the present study were approved by the Institutional Animal Care and Use Committee of the Pennington Biomedical Research Center, Baton Rouge, LA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Authors give consent to publish and reuse the material according to journal policy.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}